Author Page for Tobias Odendahl

Actions:

View:
Selected
Original List
All Versions Hide All Versions
All Abstracts Hide All Abstracts

(Rank)

Safety and Immunogenicity of a DNA SARS-CoV-2 Vaccine (Alveavax-V1.2): Results of a First-in-Human, Open-Label, Active-Controlled, Randomized Dose-Finding Study of Intradermal and Subcutaneous Application in Primary Ad26.COV2.S Vaccinated Healthy Individuals

Number of pages: 26 Posted: 27 Dec 2023

Maximilian Schons, Tobias Odendahl, James Smith, Kyle Fish, Anemone Franz, Miti Saksena, Sonia Sutherland, Vaughan Reed, Phumzile Mhlongo, Madeli Kruger, Zinhle Zwane, Kgoete Dimakatso, Carol Crowther, Penny L. Moore, Veronique De Jager, Ethan Alley and Grigory Khimulya

Alvea LLC, Alvea LLC, Alvea LLC, Alvea LLC, Alvea LLC, Alvea LLC, Micron Research Ltd, Micron Research Ltd, Ubuntu Clinical Research, Ubuntu Clinical Research, Setshaba Research Centre, Setshaba Research Centre, South African Medical Research Council - Antibody Immunity Research Unit (AIRU), University of the Witwatersrand, TASK, Alvea LLC and Alvea LLC

Downloads 56 (1,000,027)

Tobias Odendahl

Alvea LLC

1

56

0

Scholarly Papers (1)

Safety and Immunogenicity of a DNA SARS-CoV-2 Vaccine (Alveavax-V1.2): Results of a First-in-Human, Open-Label, Active-Controlled, Randomized Dose-Finding Study of Intradermal and Subcutaneous Application in Primary Ad26.COV2.S Vaccinated Healthy Individuals

Abstract: